The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block

Gastrointestinal Disease Clinical Trial

Official title: The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block - a Prospective, Single-center, Randomized, Controlled Trial

Status Completed

Clinical Trial Summary

In this single-center, randomized, parallel control clinical trial, patients will be randomly assigned to two groups. The treatment group receives ultrasound-guided erector spinae plane block with routine treatment of Acute Gastrointestinal Injury (AGI) for 7 days or until transferred to the general ward, while the control group only receives routine treatment of AGI. The primary outcome is the cure and remission rate of AGI.

Clinical Trial Description

Detailed Description: Study title: The treatment of Acute Gastrointestinal Injury via ultrasound-guided erector spinae plane block - a prospective, single-center, randomized, controlled trial Principal Investigator: Professor Wang Hua, Department of Critical Care Unit, Zhujiang Hospital of Southern Medical University Study subjects: Patients age from 18 to 80 with AGI Ⅱ or greater Study phase: Investigator Initiated Trial(IIT) Primary objectives: To evaluate whether ultrasound-guided erector spinae plane block can reduce the grade of AGI , and improve the cure and remission rate of AGI. Experimental Group: On the basis of routine clinical treatment, the ultrasound-guided erector spinae plane block intervention is given. On the first day enrolled, patients are performed with ultrasound-guided erector spinae plane block and cannula will be placed on T8 bilaterally. 0.375% ropivacaine of 20ml is injected separately to both sides with 2ml per hour. Injection is performed twice a day for 7 days or until transferred to the general ward. Controlled Group: The patients will receive the clinical routine treatment according of AGI recommended by the 2012 European Society of Critical Care Medicine guidelines, with a uniform nutritional strategy(gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy). Course: 7 days Sample size: 100 Sites: 1 Primary endpoints: 1. the cure rate of AGI 2. the remission rate of AGI Secondary endpoints: 1. critical ill scores 2. Gastrointestinal function indicators 3. The inflammatory indicators 4. the lactic acid(Lac) 5. cross-sectional area of pyloric antrum(AS) with ultrasound 6. width of the colons with abdominal X ray or CT 7. the 28-day mortality 8. gastrointestinal dysfunction and duration (GIF) Additional endpoints: 1. The length of stay in ICU 2. The total days of hospitalization ;

Related Conditions & MeSH terms

• Digestive System Diseases
• Gastrointestinal Disease
• Gastrointestinal Diseases

• NCT number: NCT04934904
• Study type: Interventional
• Source: Zhujiang Hospital
• Status: Completed
• Phase: N/A
• Start date: August 1, 2019
• Completion date: September 15, 2021